红景天苷辅助治疗中重症急性胰腺炎的机制研究

doi:10.11958/20221606

天津医药 ›› 2023, Vol. 51 ›› Issue (7): 762-765.doi: 10.11958/20221606

红景天苷辅助治疗中重症急性胰腺炎的机制研究

王小红¹(), 钱晶², 王加伟², 祁小鸣¹, 孟芸¹, 王萍¹, 程睿智¹, 周国雄³

1 南京鼓楼医院集团仪征医院消化内科（邮编211900）
2 南京鼓楼医院集团仪征医院普通外科（邮编211900）
3 南通大学附属医院消化内科

收稿日期:2022-10-09 修回日期:2023-01-18 出版日期:2023-07-15 发布日期:2023-07-18
作者简介:王小红（1974），男，主任医师，主要从事消化系统疾病诊治相关研究。E-mail：wxh_102474@163.com
基金资助:
2020年江苏省中医药科技发展计划项目(YB2020088);2020年扬州市“绿扬金凤计划”卫生创新领军人才基金项目(YZLYJF2020WSCX037);2021年扬州市重点研发项目（社会发展）(YZ2021091)

The study on the mechanism of salidroside in the adjuvant treatment of patients with moderately severe acute pancreatitis

WANG Xiaohong¹(), QIAN Jing², WANG Jiawei², QI Xiaoming¹, MENG Yun¹, WANG Ping¹, CHENG Ruizhi¹, ZHOU Guoxiong³

1 Department of Gastroenterology, Yizheng Hospital of Nanjing Drum Tower Hospital Group, Nanjing 211900, China
2 Department of General Surgery, Yizheng Hospital of Nanjing Drum Tower Hospital Group, Nanjing 211900, China
3 Department of Gastroenterology, the Affiliated Hospital of Nantong University

Received:2022-10-09 Revised:2023-01-18 Published:2023-07-15 Online:2023-07-18

王小红, 钱晶, 王加伟, 祁小鸣, 孟芸, 王萍, 程睿智, 周国雄. 红景天苷辅助治疗中重症急性胰腺炎的机制研究[J]. 天津医药, 2023, 51(7): 762-765.

WANG Xiaohong, QIAN Jing, WANG Jiawei, QI Xiaoming, MENG Yun, WANG Ping, CHENG Ruizhi, ZHOU Guoxiong. The study on the mechanism of salidroside in the adjuvant treatment of patients with moderately severe acute pancreatitis[J]. Tianjin Medical Journal, 2023, 51(7): 762-765.

摘要/Abstract

摘要：

目的探讨红景天苷调控黑色素瘤缺乏因子2（AIM2）炎性小体介导的细胞焦亡对中重症急性胰腺炎（MSAP）的辅助治疗作用效果及机制。方法将60例MSAP患者按照随机数字表法分为常规组和试验组，每组30例。2组均给予常规治疗，试验组加用红景天苷治疗。治疗前及治疗后7 d，采用酶联免疫吸附试验（ELISA）检测2组患者血清胱天蛋白酶（Caspase）-1、Gasdermin蛋白D（GSDMD）、AIM2、白细胞介素（IL）-1β及IL-18水平。评估2组患者急性生理与慢性健康评分（APACHE）Ⅱ 及胰腺改良CT严重指数（MCTSI）评分，并记录其腹痛缓解时间和住院时间。结果治疗后7 d，常规组和试验组血清Caspase-1、GSDMD、AIM2、IL-1β及IL-18水平均较治疗前下降，且试验组均较常规组下降（P<0.01）。常规组和试验组APACHE Ⅱ、胰腺MCTSI评分均较治疗前下降，且试验组较常规组均下降（P<0.01）。试验组腹痛缓解时间和住院时间较常规组均缩短（P<0.01）。结论红景天苷可通过抑制AIM2炎性小体介导的细胞焦亡，从而对MSAP患者发挥有效辅助治疗作用。

关键词: 胰腺炎, 细胞焦亡, 急性病, 危重病人医疗, 炎性小体, 黑色素瘤缺乏因子2, 红景天苷

Abstract:

Objective To observe the adjuvant therapeutic effect of salidroside on patients with moderately severe acute pancreatitis (MSAP) and explore its mechanism. Methods A total of 60 patients with MSAP were randomly divided into the routine group (30 cases) and the experimental group (30 cases) using the random number table method. A routine treatment method was given to patients in both groups, and patients in the experimental group were additionally treated with salidroside. Serum levels of cysteine-containing aspartate-specific proteases (Caspase)-1, Gasdermin D (GSDMD), absent in melanoma 2 (AIM2), interleukin (IL)-1β and IL-18 were detected by enzyme-linked immunosorbent assay (ELISA) before and 7 days after treatment in both groups. The acute physiology and chronic health evaluation (APACHE) Ⅱ and pancreas-modified CT severity index (MCTSI) scores were evaluated. The time of abdominal pain-relieving and the hospital stay were also recorded in the two groups. Results Compared with 1 d before treatment, serum levels of Caspase-1, GSDMD, AIM2, IL-1β and IL-18 decreased 7 d after treatment in both groups, and serum levels of all above indexes were significantly lower in the experimental group than those in the routine group (P<0.01). Scores of APACHE Ⅱ and pancreas-MCTSI decreased in both groups on 7 d after treatment, and scores of two indexes were significantly lower 7 d after treatment in the experimental group than those in the routine group (P<0.01). The time of abdominal pain-relieving and the hospital stay were all shorter in the experimental group than those in the routine group (P<0.01). Conclusion Salidroside can play a good adjuvant therapeutic effect on patients with MSAP by inhibiting AIM2 inflammasome-mediated pyroptosis.

Key words: pancreatitis, pyroptosis, acute disease, critical care, inflammatory corpuscles, melanoma deficiency factor 2, salidroside

中图分类号:

R576.1

图/表 4

参考文献 23

[1]	SINONQUEL P, LALEMAN W, WILMER A. Advances in acute pancreatitis[J]. Curr Opin Crit Care, 2021, 27(2):193-200. doi:10.1097/MCC.0000000000000806.
[2]	LEE P J, PAPACHRISTOU G I. New insights into acute pancreatitis[J]. Nat Rev Gastroenterol Hepatol, 2019, 16(8):479-496. doi:10.1038/s41575-019-0158-2.
[3]	MATTA B, GOUGOL A, GAO X, et al. Worldwide variations in demographics,management, and outcomes of acute pancreatitis[J]. Clin Gastroenterol Hepatol, 2020, 18(7):1567-1575.e2. doi:10.1016/j.cgh.2019.11.017.
[4]	韦碧薇, 龚雅慧, 梁志海. 细胞焦亡在急性胰腺炎发病机制中的作用[J]. 临床肝胆病杂志, 2020, 36(8):1905-1908.
	WEI B W, GONG Y H, LIANG Z H. Role of pyroptosis in the pathogenesis of acute pancreatitis[J]. J Clin Hepatol, 2020, 36(8):1905-1908. doi:10.3969/j.issn.1001-5256.2020.08.050.
[5]	ALGABA-CHUECA F, DE-MADARIA E, LOZANO-RUIZ B, et al. The expression and activation of the AIM2 inflammasome correlates with inflammation and disease severity in patients with acute pancreatitis[J]. Pancreatology, 2017, 17(3):364-371. doi:10.1016/j.pan.2017.03.006.
[6]	QIAN J, WANG X, WENG W, et al. Salidroside alleviates taurolithocholic acid 3- sulfate-induced AR42J cell injury[J]. Biomed Pharmacother, 2021, 142:112062. doi:10.1016/j.biopha.2021.112062.
[7]	QIAN J, WANG X H, WEI B Z, et al. Therapeutic effects of salidroside vs pyrrolidine dithiocarbamate against severe acute pancreatitis in rat[J]. J Tradit Chin Med, 2022, 42(1):49-57. doi:10.19852/j.cnki.jtcm.20210707.002.
[8]	WANG X, QIAN J, MENG Y, et al. Salidroside alleviates severe acute pancreatitis- triggered pancreatic injury and inflammation by regulating miR-217-5p/YAF2 axis[J]. Int Immunopharmacol, 2022, 111:109123. doi:10.1016/j.intimp.2022.109123.
[9]	中华医学会外科学分会胰腺外科学组. 急性胰腺炎诊治指南(2014版)[J]. 中华消化外科杂志, 2015, 14(1):1-5.
	Pancreatic Surgery Group of Surgery Branch of Chinese Medical Association. Guidelines for the diagnosis and treatment of acute pancreatitis (2014 edition)[J]. Chin J Dig Surg, 2015, 14(1):1-5. doi:10.3760/cma.j.issn.1673-9752.2015.01.001.
[10]	袁鹏. BISAP评分与APACHE Ⅱ 评分在早期预测急性胰腺炎严重程度中的评估比较[D]. 银川: 宁夏医科大学, 2013:1-44.
	YUAN P. A comparative evaluation of BISAP and APACHE Ⅱ scoring system in early prediction of severity in acute pancreatitis[D]. Yinchuan: Ningxia Medical University, 2013:1-44.
[11]	林果为, 王吉耀, 葛均波. 实用内科学[M]. 15版. 北京: 人民卫生出版社, 2017:1644-1650.
	LIN G W, WANG J Y, GE J B. Practice of Internal Medicine[M]. 15th ed. Beijing: People´s Medical Publishing House, 2017:1644-1650.
[12]	FONSECA SEPÚLVEDA E V, GUERRERO-LOZANO R. Acute pancreatitis and recurrent acute pancreatitis: an exploration of clinical and etiologic factors and outcomes[J]. J Pediatr(Rio J), 2019, 95(6):713-719. doi:10.1016/j.jped.2018.06.011.
[13]	袁铁超, 陈国忠, 王婕, 等. 中医多途径治疗重症急性胰腺炎的研究进展[J]. 世界中医药, 2020, 15(16):2515-2518.
	YUAN T C, CHENG G Z, WANG J, et al. Research progress on the treatment of severe acute pancreatitis by multiple approaches of traditional Chinese medicine[J]. World Chinese Medicine, 2020, 15(16):2515-2518. doi:10.3969/j.issn.1673-7202.2020.16.036.
[14]	PU W L, ZHANG M Y, BAI R Y, et al. Anti-inflammatory effects of Rhodiola rosea L.:A review[J]. Biomed Pharmacother, 2020, 121:109552. doi:10.1016/j.biopha.2019.109552.
[15]	ZHENG T, BIAN F, CHEN L, et al. Beneficial effects of rhodiola and salidroside in diabetes:potential role of AMP-activated protein kinase[J]. Mol Diagn Ther, 2019, 23(4):489-498. doi:10.1007/s40291-019-00402-4.
[16]	MAGANI S K J, MUPPARTHI S D, GOLLAPALLI B P, et al. Salidroside - can it be a multifunctional drug?[J]. Curr Drug Metab, 2020, 21(7):512-524.doi:10.2174/1389200221666200610172105.
[17]	ZHANG X, XIE L, LONG J, et al. Salidroside:A review of its recent advances in synthetic pathways and pharmacological properties[J]. Chem Biol Interact, 2021, 339:109268. doi:10.1016/j.cbi.2020.109268.
[18]	LI H Y, LIN Y J, ZHANG L, et al. Progress of pyroptosis in acute pancreatitis[J]. Chin Med J(Engl), 2021, 134(18):2160-2162. doi:10.1097/CM9.0000000000001589.
[19]	CHEN K, WANG S. Ibuprofen alleviates acute pancreatitis-(AP-) induced myocardial injury by inhibiting AIM2[J]. Comput Math Methods Med, 2022, 2022:8801484. doi:10.1155/2022/8801484.
[20]	KANG R, CHEN R, XIE M, et al. The receptor for advanced glycation end products activates the AIM2 inflammasome in acute pancreatitis[J]. J Immunol, 2016, 196(10):4331-4337. doi:10.4049/jimmunol.1502340.
[21]	KUMARI P, RUSSO A J, SHIVCHARAN S, et al. AIM2 in health and disease: inflammasome and beyond[J]. Immunol Rev, 2020, 297(1):83-95. doi:10.1111/imr.12903.
[22]	ZHANG C, CHEN M, CHI Z. Cytokine secretion and pyroptosis of cholesteatoma keratinocytes mediated by AIM2 inflammasomes in response to cytoplasmic DNA[J]. Mol Med Rep, 2021, 23(5):344. doi:10.3892/mmr.2021.11983.
[23]	FIDLER T P, XUE C, YALCINKAYA M, et al. The AIM2 inflammasome exacerbates atherosclerosis in clonal haematopoiesis[J]. Nature, 2021, 592(7853):296-301. doi:10.1038/s41586-021-03341-5.

组别	Caspase-1			GSDMD
组别	治疗前	治疗后7 d	t	治疗前	治疗后7 d	t
常规组	85.43±12.32	70.65±8.15	13.190^＊＊	94.53±12.64	79.94±8.79	12.460^＊＊
试验组	86.71±12.59	58.37±9.57	28.490^＊＊	95.39±12.87	67.73±10.53	12.510^＊＊
t	0.790	4.430^＊＊		0.490	4.610^＊＊

组别	Caspase-1			GSDMD
组别	治疗前	治疗后7 d	t	治疗前	治疗后7 d	t
常规组	85.43±12.32	70.65±8.15	13.190^＊＊	94.53±12.64	79.94±8.79	12.460^＊＊
试验组	86.71±12.59	58.37±9.57	28.490^＊＊	95.39±12.87	67.73±10.53	12.510^＊＊
t	0.790	4.430^＊＊		0.490	4.610^＊＊

组别	AIM2/（μg/L）			IL-1β/（ng/L）			IL-18/（ng/L）
组别	治疗前	治疗后7 d	t	治疗前	治疗后7 d	t	治疗前	治疗后7 d	t
常规组	2.53±0.30	1.44±0.16	19.340^＊＊	110.80±14.11	86.60±7.18	11.710^＊＊	277.19±37.74	212.21±32.40	16.120^＊＊
试验组	2.41±0.29	0.92±0.12	27.410^＊＊	112.42±14.57	70.17±5.88	14.710^＊＊	278.84±41.06	178.23±20.20	18.840^＊＊
t	1.890	12.260^＊＊		0.610	8.410^＊＊		0.510	4.420^＊＊

组别	AIM2/（μg/L）			IL-1β/（ng/L）			IL-18/（ng/L）
组别	治疗前	治疗后7 d	t	治疗前	治疗后7 d	t	治疗前	治疗后7 d	t
常规组	2.53±0.30	1.44±0.16	19.340^＊＊	110.80±14.11	86.60±7.18	11.710^＊＊	277.19±37.74	212.21±32.40	16.120^＊＊
试验组	2.41±0.29	0.92±0.12	27.410^＊＊	112.42±14.57	70.17±5.88	14.710^＊＊	278.84±41.06	178.23±20.20	18.840^＊＊
t	1.890	12.260^＊＊		0.610	8.410^＊＊		0.510	4.420^＊＊

组别	APACHEⅡ
组别	治疗前			治疗后7 d		t
常规组	10.63±1.52			9.40±1.35		10.790^＊＊
试验组	10.77±1.31			7.07±0.94		16.400^＊＊
t	0.320			7.620^＊＊
组别		胰腺MCTSI评分
组别		治疗前	治疗后7 d		t
常规组		5.33±0.61	4.40±0.50		14.000^＊＊
试验组		5.10±0.85	3.30±0.54		13.800^＊＊
t		0.460	7.040^＊＊

红景天苷辅助治疗中重症急性胰腺炎的机制研究

The study on the mechanism of salidroside in the adjuvant treatment of patients with moderately severe acute pancreatitis

引用本文

RichHTML

PDF (PC)

可视化

摘要/Abstract

使用本文

图/表 4

参考文献 23

相关文章 15

编辑推荐

Metrics

本文评价

组别	腹痛缓解时间	住院时间
常规组	6.37±1.10	13.70±1.60
试验组	3.47±0.63	9.47±0.63
t	12.550^＊＊	13.480^＊＊

[1]	叶朝阳, 马建中, 李后俊, 魏鲲鹏. 急性胰腺炎患者外周血TLR4、IL-1β、NLR水平与疾病进展和预后的关系[J]. 天津医药, 2024, 52(6): 648-652.
[2]	初吉燕, 田竞, 付笛语, 郭琳, 孙蕊, 李萍. AIM2炎症小体在急性痛风性关节炎中的表达及意义[J]. 天津医药, 2024, 52(5): 518-522.
[3]	王月, 权兴苗, 王玉, 宋春侠, 邵月, 徐立伟. 益气升清方调节HIF-1α/NLRP3信号通路对缺血性脑卒中大鼠神经元焦亡的影响[J]. 天津医药, 2024, 52(4): 350-355.
[4]	向近杰, 吕懋鑫, 王梦悦, 张坤, 李颢. Ca²⁺诱导HK-2细胞焦亡及黏附性变化对含钙肾结石形成的分子机制研究[J]. 天津医药, 2024, 52(3): 250-255.
[5]	郝建玲, 信婧婧, 王靖, 田红, 苏海涛. 连翘苷调节NLRP3炎性通路对急性胸膜炎大鼠肺损伤的影响[J]. 天津医药, 2024, 52(2): 161-166.
[6]	张晓旭, 杨文奇. 沙库巴曲缬沙坦治疗AMI后射血分数中间值心力衰竭的疗效研究[J]. 天津医药, 2024, 52(2): 177-181.
[7]	王伟, 夏铭, 张玲, 郭庆红. 十二指肠镜下胆总管取石术后发生胰腺炎的影响因素分析[J]. 天津医药, 2024, 52(12): 1305-1308.
[8]	梁耀冰, 符振华, 赵梓粤, 罗剑明, 程冬瑀, 姜海行, 覃山羽. 高甘油三酯血症性急性胰腺炎并发急性呼吸衰竭危险因素及预测模型的建立[J]. 天津医药, 2024, 52(11): 1183-1187.
[9]	张桂贤, 刘大卫, 李文畅, 蔡隽, 宗文辉, 刘洪斌, 赵秀梅. BOC2抑制N-甲酰肽/甲酰肽受体信号通路减轻SAP炎症损伤的机制研究[J]. 天津医药, 2024, 52(10): 1031-1037.
[10]	杨文珊, 盛玉, 陈秀利, 陈吉. 小儿急性胰腺炎序贯化营养支持与肠外营养支持的疗效比较[J]. 天津医药, 2024, 52(10): 1061-1064.
[11]	刘国旗, 李程程, 刘声菊, 朱丽英. 大黄素调控组蛋白乙酰化促进HpG2肝癌细胞焦亡及凋亡的发生[J]. 天津医药, 2024, 52(1): 56-60.
[12]	陈玺龙, 王宏君, 宋征宇, 王静. 牛蒡苷元通过抑制HMGB1/TLR4/NF-κB通路减轻急性脑梗死大鼠的神经元损伤[J]. 天津医药, 2023, 51(8): 825-829.
[13]	程炯炯, 李琳琳, 赵浩东, 胡志旭, 陈卫东, 王兴宇. CRRT联合血浆置换救治高脂血症性重症急性胰腺炎患者的疗效分析[J]. 天津医药, 2023, 51(8): 855-859.
[14]	孙立燕, 刘泽茹, 苏永胜, 艾宏亮. 车叶草苷调节NLRP3/Caspase-1/GSDMD信号通路对脓毒症大鼠肺组织细胞焦亡的影响[J]. 天津医药, 2023, 51(6): 607-612.
[15]	曾家月, 马昕玥, 马凤雨, 陈霞. 尿石素A通过TLR4/NF-κB信号通路对重症急性胰腺炎的保护作用及机制[J]. 天津医药, 2023, 51(6): 613-617.